Review of the Antifungal Drug Luconazole for the Treatment of Skin Infections

Authors

  • ARCHANA SANKHWAR Research Scholar, Department of Biotechnology, Advance Institute of Biotech & Paramedical Sciences, Kanpur, Uttar Pradesh
  • Shruti Khare Assistant Professor, Department of Biotechnology, Advance Institute of Biotech & Paramedical Sciences, Kanpur, Uttar Pradesh

Abstract

Many U.S. researchers are still working on a broad-spectrum imidazole antifungal called Luliconazole to treat dermatophytic skin and nail infections. The in vitro activity of luliconazole against filamentous fungi, including dermatophytes, is among the highest of any antifungal drug tested to date. The unique molecular characteristics of a 10% solution of Luliconazole make it possible for the drug to quickly reach fungicidal concentrations in the nail unit, allowing it to permeate the nail plate. Given these characteristics, luliconazole is an effective medication for treating onychomycosis. This essay will discuss the history of luliconazole solution, 10% of its molecular characteristics, preclinical and clinical data, and its potential use in the future treatment of fungal infections. Dermatophytic skin and nail infections are being treated in the United States using luconazole, a new, broad-spectrum imidazole antifungal. Among the most effective antifungal medicines in vitro, luliconazole is effective against dermatophytes and other filamentous fungi. With its special molecular characteristics, a 10% solution of luliconazole can quickly reach fungicidal levels in the nail unit and penetrate the nail plate. Onychomycosis is effectively treated with luliconazole due to its powerful characteristics. Future prospects for the treatment of fungal infections are discussed, along with the history of luliconazole solution (10%), its molecular characteristics, preclinical data, and clinical data.

References

Scher RK, Nakamura N, Tavakkol A. Luliconazole: A review of a new antifungal agent for the topical treatment of onychomycosis. Mycoses. 2014; 57 (7): 389–93.

Koga H, Nanjoh Y, Makimura K, Tsuboi R. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol. 2009; 47 (6): 640–7.

Alhakamy NA, Al-Rabia MW, Md S, Sirwi A, Khayat SS, Alotaibi SS, et al. Development and optimisation of luliconazole plastics to augment the antifungal activity against candida Albicans. Pharmaceutics. 2021;13 (7).

Zargaran M, Taghipour S, Kiasat N, Aboualigalehdari E, Rezaei-Matehkolaei A, Zarei Mahmoudabadi A, et al. Luliconazole, an alternative antifungal agent against Aspergillus terreus. J Mycol Med [Internet]. 2017; 27 (3): 351–6. Available from: http://dx.doi.org/10.1016/ j.mycmed.2017.04.011

Salehi Z, Fatahi N, Taran M, Izadi A, Badali H, Hashemi SJ, et al. Comparison of in vitro antifungal activity of novel triazoles with available antifungal agents against dermatophyte species caused tinea pedis. J Mycol Med [Internet]. 2020; 30 (2): 100935. Available from: https://doi.org/10.1016/j.mycmed.2020.100935

Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: An evidence-based review. Core Evid. 2014; 9: 113–24.

Brescini L, Fioriti S, Morroni G, Barchiesi F, Schwarz P, Dannaoui E. Antifungal combinations in dermatophytes. mdpi.com [Internet]. 2021 [cited 2022 Aug 26]; Available from: https://www.mdpi.com/1259168

dos Santos Porto D, Bajerski L, Donadel Malesuik M, Soldateli Paim C. A Review of Characteristics, Properties, Application of Nanocarriers and Analytical Methods of Luliconazole.Crit Rev Anal Chem [Internet]. 2021; 0 (0): 1–8. Available from: https://doi.org/10.1080/ 10408347.2021.1926219

Garg AK, Maddiboyina B, Alqarni MHS, Alam A, Aldawsari HM, Rawat P, et al. Solubility enhancement, formulation development and antifungal activity of luliconazole liposomal gel-based system. J Biomater Sci Polym Ed [Internet]. 2021; 32 (8): 1009–23. Available from: https://doi.org/10.1080/09205063.2021.1892471

El-Alamin MA, Sultan M, … MA-… C& H, 2020 undefined. Novel Application of Pentabromobenzyl Column for Simultaneous Determination of Eight Antifungal Drugs Using High-performance Liquid Chromatography. ingentaconnect.com [Internet]. 2020 [cited 2022 Aug 26]; Available from: https://www.ingentaconnect.com/content/ben/cchts/2020/00000023/ 00000010/art00003

Koga H, Tsuji Y, Inoue K, Kanai K, Majima T, Kasai T, et al. In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses. J Infect Chemother. 2006; 12 (3): 163–5.

Tiwari S, Prajapati RN, Deo Yadav R, Chanchal DK, Mansoori MF, Gupta S. Pamam dendrimer-based luliconazole gel formulation and efficiency evaluations. ejmcm.com [Internet]. [cited 2022 Aug 26]; Available from: https://www.ejmcm.com/article_7218_4a1c6cedf7072b51ad3b490 716a44db5.pdf

Devi L, Gupta R, Jain SK, et al. Synthesis, characterization and in vitro assessment of colloidal gold nanoparticles of Gemcitabine with natural polysaccharides for treatment of breast cancer. J Drug Deliv Sci Technol. 2020; 56: 11–18.

Kesharwani P, Banerjee S, Gupta U, et al. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics. Mater Today. 2015; 18 (10): 565–572.

Bongomin F, Gago S, Oladele RO, et al. Global and multi-national prevalence of fungal diseases – estimate precision. JoF. 2017; 3 (4): 57.

Tripathi PK, Gorain B, Choudhury H, et al. Dendrimer entrapped microsponge gel of dithranol for effective topical treatment. Heliyon. 2019; 5 (3): e01343.

Downloads

Published

2022-11-03

Issue

Vol. 9 No. 2 (2022)

Section

Articles

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.